Newsletter | February 6, 2025

02.06.25 -- Developing ADCs? A Refresher On HPAPI Occupational Health Risk Mitigation

FEATURED EDITORIAL

Developing ADCs? A Refresher On HPAPI Occupational Health Risk Mitigation

API payloads used in antibody-drug conjugates are some of the most potent substances in biopharma, so it's important to protect workers who handle them.

Suffering High Protein Sieving Losses? It Might Be The Buffer

New research shows that a common buffer used during diafiltration and ultrafiltration was at the heart of sieving losses, and using an alternative dramatically improved retention.

INDUSTRY INSIGHTS

Establishing Commercial Manufacturing Services For ADCs

Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.

NEWS HEADLINES

Tanvex BioPharma Completes Acquisition Of Bora Biologics, Launching New Era In Biologics Development

Alvotech And Teva Announce Filing Acceptance Of U.S. Biologics License Applications For AVT05, A Proposed Biosimilar To Simponi® And Simponi Aria® (golimumab)

Kashiv Biosciences Announces Successful Phase 1 Results For Abatacept Biosimilar Candidate, KSHB002

U.S. FDA Approves Celltrion's AVTOZMA® (tocilizumab-anoh), A Biosimilar To ACTEMRA®

SOLUTIONS

Modular Chromatography System For Liquid Chromatography